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Introduction
Mevalonate kinase deficiency (MKD) is a rare hereditary
autoinflammatory syndrome, characterized by recurrent
fever episodes with gastrointestinal complaints, rash and
arthralgia. In patients suffering from MKD, the reduced
enzyme activity leads to an accumulation of mevalonic
acid which is excreted in the urine. Therefore, an ele-
vated mevalonic acid excretion is suggestive of MKD.
However, the diagnostic value of this analysis has not
been investigated yet and remains unclear.
Objectives
To investigate the diagnostic value of urinary mevalonic
acid excretion in patients with suspected MKD.
Patients and methods
In this retrospective analysis, all patients in whom both
measurement of mevalonic acid and genetic testing had
been performed in the preceding 17 years have been
included. Samples were analyzed by using gas chromato-
graphy-mass spectrometry (GC-MS) and concentrations
were expressed as mmol/mol creatinine. The excretion of
mevalonic acid was compared with age dependent refer-
ence values, validated at our hospital. The presence of two
pathogenic MVK mutations was considered to be the gold
standard for the diagnosis of MKD.
Results
This study included 62 patients (33 male, 29 female,
aged: 0-36 year) with clinical features suggestive of MKD.
Thirteen patients harboured two MVK mutations,
twelve of them excreted elevated amounts of mevalonic
acid. In one patient mevalonic acid could not be detected,
despite the fact that urine was collected during a febrile
episode. Six patients had an elevated mevalonic acid excre-
tion, but harboured no MVK mutations. However,
repeated measurements in all six patients were ultimately
normal.
This resulted in a sensitivity of 92%, a specificity of
88%, a positive predictive value of 68% and a negative
predictive value of 98%. The positive likelihood ratio is
7.7 and the negative likelihood ratio is 0.09.
Conclusion
MKD seems very unlikely in patients with a normal meva-
lonic acid excretion, but it cannot be excluded completely.
Furthermore, a positive urinary mevalonic acid excretion
requires MVK analysis to confirm the diagnosis MKD.
However, as long as genetic testing is not widely available
and affordable, measurement of urinary mevalonic acid is
a fair way to select patients for MVK-gene analysis.
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